225 related articles for article (PubMed ID: 15097264)
1. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
2. Allergic reactions to brimonidine in patients treated for glaucoma.
Blondeau P; Rousseau JA
Can J Ophthalmol; 2002 Feb; 37(1):21-6. PubMed ID: 11865954
[TBL] [Abstract][Full Text] [Related]
3. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
Williams GC; Orengo-Nania S; Gross RL
J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
[TBL] [Abstract][Full Text] [Related]
4. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure.
Watts P; Hawksworth N
Eye (Lond); 2002 Mar; 16(2):132-5. PubMed ID: 11988811
[TBL] [Abstract][Full Text] [Related]
5. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
[TBL] [Abstract][Full Text] [Related]
6. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
Gordon RN; Liebmann JM; Greenfield DS; Lama P; Ritch R
Eye (Lond); 1998; 12 ( Pt 4)():697-700. PubMed ID: 9850267
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine allergy presenting as vernal-like keratoconjunctivitis.
Shah AA; Modi Y; Thomas B; Wellik SR; Galor A
J Glaucoma; 2015 Jan; 24(1):89-91. PubMed ID: 23632412
[TBL] [Abstract][Full Text] [Related]
8. Alphagan allergy may increase the propensity for multiple eye-drop allergy.
Osborne SA; Montgomery DM; Morris D; McKay IC
Eye (Lond); 2005 Feb; 19(2):129-37. PubMed ID: 15254495
[TBL] [Abstract][Full Text] [Related]
9. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
10. The benefit of scratch patch testing to demonstrate ocular contact allergy to brimonidine tartrate.
Ringuet J; Lajoie C; Bourgault S; Simonyan D; Houle MC
Contact Dermatitis; 2022 Oct; 87(4):336-342. PubMed ID: 35642327
[TBL] [Abstract][Full Text] [Related]
11. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy.
Motolko MA
Curr Med Res Opin; 2008 Sep; 24(9):2663-7. PubMed ID: 18691444
[TBL] [Abstract][Full Text] [Related]
12. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.
Becker HI; Walton RC; Diamant JI; Zegans ME
Arch Ophthalmol; 2004 Jul; 122(7):1063-6. PubMed ID: 15249377
[No Abstract] [Full Text] [Related]
13. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
Aristodemou P; Baer R
Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension.
Kim CY; Hong S; Seong GJ
J Ocul Pharmacol Ther; 2007 Oct; 23(5):481-6. PubMed ID: 17900227
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Schuman JS
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
[TBL] [Abstract][Full Text] [Related]
16. Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up.
Yeh PH; Cheng YC; Shie SS; Lee YS; Shen SC; Chen HS; Wu WC; Su WW
Medicine (Baltimore); 2021 Jul; 100(29):e26724. PubMed ID: 34398046
[TBL] [Abstract][Full Text] [Related]
17. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
18. Dermatological side effects of brimonidine: a report of three cases.
Sodhi PK; Verma L; Ratan J
J Dermatol; 2003 Sep; 30(9):697-700. PubMed ID: 14578562
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Simmons ST;
Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
[TBL] [Abstract][Full Text] [Related]
20. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]